(NASDAQ: HCM) Hutchmed's forecast annual revenue growth rate of 9.36% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 120.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.08%.
Hutchmed's revenue in 2025 is $630,201,000.On average, 21 Wall Street analysts forecast HCM's revenue for 2025 to be $533,428,586,151, with the lowest HCM revenue forecast at $455,272,115,962, and the highest HCM revenue forecast at $603,714,498,452.  On average, 21 Wall Street analysts forecast HCM's revenue for 2026 to be $616,047,653,946, with the lowest HCM revenue forecast at $510,793,105,714, and the highest HCM revenue forecast at $752,156,880,941.  
In 2027, HCM is forecast to generate $722,452,715,624 in revenue, with the lowest revenue forecast at $568,022,433,612 and the highest revenue forecast at $941,329,182,600.